Table 2 Patient characteristics and nrTMS and DCS language mapping parameters used in the 50 glioma patients with left-side brain regions.

From: Navigated repetitive transcranial magnetic stimulation as preoperative assessment in patients with brain tumors

Pt No.

Age

Sex

Handedness

Tumor location

Tumor volume

Pathology

WHO grade

RMT

Hz

No. of pulses

%RMT

DCS intensity (mA)

Involvement of language regions

Preoperative language disturbance

Postoperative transient language disturbance

Postoperative permanent language disturbance

        

(%)

 

in Train

(%)

     

1

67

M

R

Insular

107.6

AA

III

57

5

10

100

4

+

+

+

+

2

64

M

R

Frontal

85.1

DA

II

50

10

10

100

4

+

3

41

M

R

Frontal

8.8

OA

II

55

10

10

100

3

+

4

63

M

R

Insular

85.1

DA

II

40

5

10

100

4

+

5

72

M

R

Insular

24.9

DA

II

50

5

10

80

4

+

6

28

M

R

Parietal

0.6

PXA

II

48

5

10

80

4

7

39

M

R

Insular

61.7

DA

II

45

5

10

80

3

8

43

M

R

Frontal

101.9

AO

III

50

5

10

100

3

+

+

9

38

F

R

Insular

85.5

DA

II

53

5

10

80

4

10

18

M

R

Insular

109.4

GBM

IV

45

5

10

100

4

+

+

+

+

11

29

M

R

Insular

45.3

DA

II

40

7

10

80

4

+

12

44

M

R

Frontal

14.7

DA

II

46

5

10

100

4

13

46

M

R

Temporal

25.7

GBM

IV

50

5

10

80

3

+

14

59

M

R

Insular

91.8

AO

III

32

5

10

100

2.5

15

33

M

R

Insular

12.2

OG

II

50

5

10

100

3

+

16

30

F

R

Frontal

18.8

DA

II

35

5

10

100

3

17

57

M

R

Frontal

105.3

DA

II

38

5

10

100

3

+

18

20

M

R

Frontal

19.7

DNT

I

43

5

10

100

3

+

19

27

M

R

Frontal

50.2

DA

II

55

5

10

60

3

+

20

44

M

R

Frontal

39.7

DA

II

45

5

10

80

3

21

42

M

R

Parietal

86

DA

II

45

5

10

80

3

+

+

+

22

67

M

R

Temporal

79.3

AA

III

50

5

10

80

8

+

+

+

+

23

31

F

R

Temporal

57.8

AA

III

50

5

10

80

6

+

24

45

M

R

Temporal

27.5

AA

III

42

5

10

80

4

+

25

60

F

R

Parietal

38.3

AO

III

45

5

10

80

3

+

+

26

47

F

R

Temporal

29.2

DA

II

42

5

10

80

3

+

27

29

M

R

Frontal

10.6

AA

III

40

5

10

80

3

28

45

M

R

Frontal

51.3

DA

II

55

5

10

80

3

+

29

40

F

R

Frontal

8.7

OG

II

45

5

10

80

3

30

23

F

R

Frontal

41.1

DNT

I

48

5

10

80

3

31

20

M

R

Temporal

22.4

Pilo

I

40

5

10

80

4

+

32

33

F

R

Frontal

50.1

DA

II

50

5

10

80

3

33

23

F

R

Temporal

14.4

AA

III

36

5

10

100

2.5

34

35

F

R

Frontal

62.2

OG

II

40

5

10

80

1.5

+

+

35

53

M

R

Insular

55.1

DA

II

46

5

10

80

1.5

+

36

18

M

R

Frontal

17.8

DA

II

46

5

10

80

3

37

34

M

R

Temporal

22.4

DA

II

45

5

10

80

3

+

+

38

67

F

R

Insular

40.1

DA

II

45

5

10

80

3

+

39

43

M

R

Frontal

9

AA

III

48

5

10

80

3

+

+

40

27

F

R

Insular

177.3

DA

II

48

5

10

80

3

+

+

41

26

M

R

Frontal

30.7

AA

III

47

5

10

80

3

42

29

F

R

Temporal

69.6

AA

III

47

5

10

80

3

+

43

34

F

R

Parietal

43.2

OG

II

41

5

10

80

3

+

+

44

31

M

R

Frontal

9.4

DA

II

46

5

10

80

3

45

68

M

R

Frontal

12.6

AO

III

40

5

10

80

2.5

+

46

58

F

R

Frontal

8.4

DA

II

40

5

10

80

2.5

+

47

36

M

R

Frontal

84.2

OG

II

48

5

10

60

2.5

48

38

F

R

Parietal

14.2

DA

II

45

5

10

60

1.5

49

60

F

R

Frontal

111.5

AA

III

48

5

10

80

2

+

50

28

F

R

Frontal

120.5

AO

III

46

5

10

80

2.5

  1. Abbreviation: nrTMS; navigated repetitive transcranial magnetic stimulation, DCS; direct cortical stimulation, RMT; resting motor threshold; %RMT; stimulation intensity in percentage resting motor threshold, Pilo; pilocytic astrocytoma, DNT; dysembryoplastic neuroepithelial tumor, PXA; pleomorphic xanthoastrocytoma, DA; diffuse astrocytoma, OG; oligodendroglioma, AA; anapalastic astrocytoma, AO; anaplastic oligodendroglioma, GBM; glioblastoma.